The coronavirus impact results in inaccessibility of several of Syneos Health's (SYNH) clinical trial sites.
Potential Syneos Health, Inc. (NASDAQ:SYNH) shareholders may wish to note that the Chief Financial Officer, Jason...
Highlights GAAP revenue of $1,163.4 million for the three months ended March 31, 2020, representing growth of 4.0%, 3.8% on an adjusted basis, and 4.4% on a constant currency.
A Morrisville-based contract research organization is spreading the word about a COVID-19 treatment using a common hospital apparatus in order to stem off some of the demand for ventilators in low supply.
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.
www.COVID-BiPAPInfo.com Provides Practical Information for Physicians on Innovative Use of BiPAP Machines – Already Available in Many Hospitals – to Potentially Delay or Remove.
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
MORRISVILLE, N.C., May 22, 2020 -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research.
MORRISVILLE, N.C., May 13, 2020 -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research.
Syneos Health® (SYNH), the only fully integrated biopharmaceutical solutions organization, today announced operational and financial updates related to the COVID-19 pandemic. “Syneos Health is committed to supporting and preserving the health and safety of our employees, customers and industry colleagues across the globe, all of whom are joining together to battle COVID-19,” said Alistair Macdonald, Chief Executive Officer of Syneos Health. First Quarter 2020 Performance: During the first quarter of 2020, Syneos Health continued to build on the strong operational and financial performance the Company highlighted in its fourth quarter and year-end 2019 earnings announcement on February 20, 2020.
Alongside ACRO, Syneos Health to Provide Support for COVID-19 Testing Centers;Company Continues Public Service Educational Program to Address Ventilator Shortage MORRISVILLE,.
Over the first quarter of 2020, more than $31 billion in value disappeared from the books of local public companies that collectively employ more than a hundred thousand workers in the Triangle and across the U.S.
Daiichi Sankyo, Inc. (hereafter, Daiichi Sankyo) announced that it has entered into a strategic agreement with Syneos Health® (Nasdaq:SYNH). The companies are coming together to form a coalition to accomplish their shared goal of bringing promising cancer therapies to patients as safely, effectively and efficiently as possible.
The primary aim of this initiative by Syneos Health (SYNH) is to address the predicted ventilator deficiency in the wake of the coronavirus pandemic.
SYNH earnings call for the period ending March 31, 2020.
Syneos Health (SYNH) delivered earnings and revenue surprises of 9.68% and 2.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
Q1 2020 Syneos Health Inc Earnings Call
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.